Niagen Bioscience, Inc.

Niagen Bioscience Inc. has expanded distribution of its Tru Niagen healthy-aging NAD+ supplement onto Walmart.com, initially offering 300 mg bottles in 30- and 90-count formats, while a new peer-reviewed analysis in Aging Cell linked its nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration. The Walmart.com launch places the product on a platform that generated US$27,100 million in U.S. e-commerce net sales and US$16,400 million in U.S. health and wellness net sales last quarter. The company reported slightly lower quarterly sales and net income year on year in early August 2026. Some analysts project revenue near US$225 million and earnings around US$41 million by 2029, though more cautious views see the clinic and injection channel as a niche opportunity.

Niagen Bioscience reported strong e-commerce growth in its second quarter of 2026, with TrueNiagen website sales up 23% year-over-year and Amazon sales up 10%, a figure that would have been approximately 19% absent a temporary platform issue. The company's China cross-border channel surpassed its full-year 2025 revenue by May 2026, signaling significant growth potential in that market. Net income declined to $1 million, or $0.01 per diluted share, compared to $0.05 per diluted share a year earlier, while selling and marketing expenses rose to 34% of net sales from 26.4%. The company holds $66.7 million in cash with no debt and a $14.6 million remaining share repurchase authorization, and it is advancing its pharmaceutical pipeline with NB4168, which has received rare pediatric disease and orphan drug designations and could qualify for a transferable priority review voucher worth approximately $150 million.

The biotechnology industry for life extension is attracting funds from global billionaires. One key technology is Senolytics, the development of drugs that destroy zombie cells, which are a cause of degenerative diseases. From an investment perspective, there are two interesting groups of listed companies. The first is Unity Biotechnology, a pioneer in developing localized Senolytic drugs, such as treatments for age-related macular degeneration, with strengths in intellectual property and a network of world-class researchers. The second is ChromaDex Corporation, which holds patents and manufactures NAD+ precursors under a business model of wholesale and direct-to-consumer sales, generating stable recurring revenue. Investing in this theme should therefore diversify risk between high-risk pioneers and cash-flow-generating infrastructure players.

Niagen Bioscience Inc. has renamed its ChromaDex External Research Program to the Niagen Research Program, underscoring a renewed focus on advancing the understanding and applications of NAD+. The program supports more than 175 ongoing and developing research studies and provides oral Niagen research materials along with technical support. Independent investigators from institutions such as Mayo Clinic, the National Institutes of Health, and Cambridge University have repeatedly requested Niagen for preclinical research and NAD+ biology. Research under the program continues to explore NAD+ and Niagen across areas including skeletal and brain tissues, cellular energy metabolism, and cardiovascular health.